ストックスクリーナーアプリを入手
5.92
4.38%
-0.25
前日終値:
$6.17
開ける：
$6.11
24時間の取引高:
696.07K
Relative Volume:
3.50
時価総額：
$127.10M
収益：
-
当期純損益:
$-117.17M
株価収益率:
-4.4511
EPS:
-1.33
ネットキャッシュフロー:
$-91.71M
1週間 パフォーマンス:
-18.62%
1か月 パフォーマンス:
-28.57%
6か月 パフォーマンス:
-24.94%
1年 パフォーマンス:
-31.40%
1日の値動き範囲:
$5.82
$6.16
1週間の範囲:
$5.82
$7.7288
52週間の値動き範囲:
$5.82
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
名前
Adverum Biotechnologies Inc
セクター
電話
(650) 649-1004
住所
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ADVM | 5.91 | 127.10M | 0 | -117.17M | -91.71M | -1.33 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.40 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.04 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-07 | アップグレード | Truist | Hold → Buy |
| 2021-07-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | ダウングレード | Truist | Buy → Hold |
| 2020-12-16 | 開始されました | UBS | Neutral |
| 2020-11-12 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-05 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-09-13 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-06-14 | 再開されました | Raymond James | Mkt Perform |
| 2018-11-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | ダウングレード | SunTrust | Buy → Hold |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 開始されました | SunTrust | Buy |
| 2018-02-15 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Adverum Biotechnologies Inc (ADVM) 最新ニュース
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum Biotechnologies Grants 55,000 Share Stock Option Package to New Employee | ADVM Stock News - StockTitan
Adverum Biotechnologies (NASDAQ:ADVM) Receives "Buy" Rating from HC Wainwright - MarketBeat
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients (NASDAQ:ADVM) - Seeking Alpha
Adverum Biotechnologies Announces Positive 52-Week LUNA and - GlobeNewswire
Adverum Biotechnologies, Inc. Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 5.9% in October - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Adverum to present gene therapy data for eye disease - Investing.com India
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - The Manila Times
Adverum to present gene therapy data for eye disease By Investing.com - Investing.com UK
Adverum Biotechnologies Announces Webcast to Report 52-Week - GlobeNewswire
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
FMR LLC Reduces Stake in Adverum Biotechnologies Inc - GuruFocus.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is BML Capital Management LLC's 6th Largest Position - MarketBeat
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles By Investing.com - Investing.com Nigeria
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces hurdles - Investing.com India
HC Wainwright Issues Pessimistic Forecast for ADVM Earnings - Defense World
Morgan Stanley's Strategic Reduction in Adverum Biotechnologies Inc Shares - GuruFocus.com
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Posts Earnings Results - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies names new chief commercial officer - Investing.com
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan
Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat
Adverum Biotechnologies to Host Webcast to Review Clinical - GlobeNewswire
ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com
Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat
(ADVM) Trading Advice - Stock Traders Daily
Logos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat
Adverum Biotechnologies Inc (ADVM) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):